Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858314 | 0.79 | MAPT (0.48) | MAPTMAPK10PPARGFABP4TP53 | |
| SCHEMBL7035429 | 0.78 | MAPT (0.46) | MAPTMAPK10PPARGFABP4FOLH1 | |
| SCHEMBL24482780 | 0.78 | CCR2 (0.65) | MAPTMAPK10PPARGFABP4FOLH1 | |
| SCHEMBL6300362 | 0.78 | MAPT (0.57) | MAPTMAPK10PPARGFABP4TP53 | |
| SCHEMBL6859418 | 0.76 | PPARG (0.47) | MAPTMAPK10PPARGFABP4TP53 | |
| SCHEMBL6858382 | 0.76 | PPARG (0.76) | MAPTMAPK10PPARGEDNRBEDNRA | |
| SCHEMBL24482672 | 0.76 | MAPT (0.55) | MAPTMAPK10PPARGFABP4TP53 | |
| SCHEMBL24482668 | 0.76 | MAPT (0.55) | MAPTMAPK10PPARGFABP4LMNA | |
| SCHEMBL24482667 | 0.75 | MAPT (0.54) | MAPTMAPK10PPARGFABP4TP53 | |
| SCHEMBL24482671 | 0.74 | MAPT (0.53) | MAPTMAPK10PPARGFABP4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| CN-1505613-A | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents | ʷ��˿�������ȳ�ķ����˾ | 2004-06-16 | — | — | CN | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | MAPT 3447/4885MAPK10 1496/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.